Brief: U.S. FDA Approves Bristol Myers Squibb And 2seventy bio’s Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy

2Seventy Bio

05/04/2024 14:45

April 5 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * U.S. FDA APPROVES BRISTOL MYERS SQUIBB AND 2SEVENTY BIO’S
ABECMA
FOR TRIPLE-CLASS EXPOSED RELAPSED OR REFRACTORY MULTIPLE MYELOMA
AFTER TWO PRIOR LINES OF THERAPY
    * BRISTOL-MYERS SQUIBB: ABECMA APPROVED IN U.S., JAPAN,
SWITZERLAND,EU FOR EARLIER USE FOR TRIPLE-CLASS EXPOSED RELAPSED
& REFRACTORY MULTIPLE MYELOMA
    * BRISTOL-MYERS SQUIBB: FDA APRROVAL CONTAINS BOXED WARNING
FOR
CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS,
PROLONGED CYTOPENIA
    * BRISTOL-MYERS SQUIBB: FDA APRROVAL CONTAINS BOXED WARNING
FOR
SECONDARY HEMATOLOGICAL MALIGNANCIES

Source text for Eikon:  ID:nBw3LNFrga 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))